Sudarshan Pharma Industries Ltd · BSE:SUDARSHAN
Sudarshan Pharma Industries — Investor Presentation (August 2026)
48 slides from Sudarshan Pharma Industries's investor presentation, Nov 7, 2026
Slide 1: Stock exchange filing cover letter
SPIL/CS/SE/2026-2027/75 Date: 07th November 2026 To, The Listing Department The Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 BSE Scrip
Slide 2: Sudarshan Pharma Industries Limited Investor Presentation
Sudarshan Pharma Industries Limited “Innovating Chemistry, Empowering Health” INVESTOR PRESENTATION August 2026 E-mail : Compliance@sudarshanpharma.com Website : www.sudarshanpharma.com Contact No : CS Nirav shah : 7700966328
Slide 3: NSE Listing Ceremony milestone
SUDARSHAN | => NSE PHARMA INDUSTRIES Fes] ofindia Lawitea 27 fecisete Gforce FOR BEING A PART OF OUR ——— — < A Proud Milestone in the Journey of Sudarshan Pharma Industries Limited! Sudarshan Pharma Industries Limited proudly celebrates its NSE Listing Ceremony at the National Stock Exchange of Indi
Slide 4: Slide 4
Slide 5: Limited
Limited
Slide 6: Company Background & Overview
COMPANY BACKGROUND & OVERVIEW Sudarshan Pharma Industries Limited | Investor Presentation
Slide 7: A Specialty Chemicals & Pharmaceutical Trading and Manufacturing Company
A Specialty Chemicals & Pharmaceutical Trading and Manufacturing Company 18 Years Founded in 2008, Sudarshan Pharma Industries Limited (SPIL) is engaged in manufacturing and sourcing of Chemicals and Pharmaceutical products Diversified Products The Company specializes in host of products from rock c
Slide 8: Milestones
Milestones 2008- 2011- 2013- 2015- 2017- 2010 2012 2014 2016 2018 • 2008 ‐ Expanded • Generic • Established our • Over 5,000 medical • Manufacturing of market reach by formulations for footprints in practitioners Nutraceuticals. importing high- institution supply, Gujarat, West associated with quali
Slide 9: Milestones
Milestones 2019- 2021- 2023- 2024- 2025- 2020 2022 2024 2025 2026 • *Nutraceuticals • IVD-Section Got • New unit • Incorporated • Proposed Plant project cost 50Cr. Govt. Order. development in Sudarshan Maven Allotment of FCCB is Rs. 2.5 Cr. And • Successfully Palghar. Pharma Private of 20 Million US
Slide 10: Existing Business Layout
Business Layout Existing Business Layout The company is focusing on increasing manufacturing capabilities and has started Vertical Integration for expansion in the following segments: Branded Generics Finished Formulation and F&O Research & API Manufacturing Development and Import Intermediates for
Slide 11: Subsidiaries
Subsidiaries SUDARSHAN PHARMA INDUSTRIES LTD. Wholly Owned Subsidiaries 51% Ownership Ratna Lifescience Pvt. Ltd. Life Science Chemical Sudarshan Industries Ishwari Healthcare Pvt. Ltd. Pvt. Ltd. INC, USA ((now divested) Existing Products: Existing Products: Existing Products: •Gemcitabine • Tannin
Slide 12: Subsidiaries
Subsidiaries SUDARSHAN PHARMA INDUSTRIES LTD. Wholly Owned Subsidiaries 70% Ownership Sudarshan Pharma Cibachem General Trading Sudarshan Maven Industries Private Limited, Sudarshan Pharma Lifescience Private LLC, Dubai Pharma Private Limited Singapore Limited Trading activities of all Existing Prod
Slide 13: Key Products
Key Products SPECIALITY GREEN CHEMICALS Key Products Acetonitrile Tetrahydrofuran (THF) 1, 4-Dioxane DMF/DMSO NMP (N-Methyl-2- Meta xylene N-Heptane Diethanolamine pyrrolidone) PHARMA DIVISION Out of 96 products, 56 are registered under the “R” Trade Mark. • SPIL has introduced a novel drug delivery
Slide 14: Key Products
Key Products PERFORMANCE CHEMICALS & INTERMEDIATE CAMPAIGN BASIS • Specialize Performance Chemials • Sesamol (3,4-(Methylenedioxy)phenol) CAS. 533-31-3 (Having Patent Filled on April 16th 2026). • 4-((4-Fluorophenyl)imino)methyl)phenol CAS. 3382-63-6 • (S)-3-[5-(4-Fluorophenyl)-1,5-dioxopentyl]-4-ph
Slide 15: Key Products
Key Products PERFORMANCE CHEMICALS & INTERMEDIATE CAMPAIGN BASIS • 1-(2-Ethoxyethyl)-2-(piperidin-4-yl)-1H-benzo[d]imidazole Hydrochloride Sesquihydrate CAS.1841081-72-8 • 4-Hydrazinobenzoic acid CAS. 24589-77-3 • (S)-1-(2-Chloroacetyl)pyrrolidine-2-carbonitrile CAS. 20757-35-5 • 3 – Amino – 1 – Ada
Slide 16: Export Opportunity
Export Opportunity In FY 25-26: We Targeted Majorly on our Own Manufacturing API Products Including (Oncology) and Finish Formulation (Keeping Products Registration on priority) and Non-Regulated Market for which we have made the Loan Licsenses with many Manufacturers to be Cost Effective and Qualit
Slide 17: Operating in over 10 countries globally
Operating in over 10 countries globally Exporting Countries Lebanon Jordan Nepal Qatar Saudia UAE Arabia Mali Bangladesh Oman Nigeria Sri Lanka Uganda Ghana Somalia Congo Kenya South Africa PAN India presence Sudarshan Pharma Industries Limited | Investor Presentation
Slide 18: Ratna Lifescience: Turnaround story
Ratna Lifescience : Turnaround story Revenue from Operations (Rs Cr) Profit After Tax (Rs Cr) 35.30 Prior to take-over, Ratna Life was operating 9.22 +7.8 at a loss. Since the takeover by the +7.1 +0.51 Company, Ratna Life has turned around into 2.15 a profitable organization, achieving 0.02 -0.87 s
Slide 19: Sudarshan Pharma – Srigen New Manufacturing Unit
SUDARSHAN PHARMA – SRIGEN NEW MANUFACTURING UNIT Hyderabad Unit Hyderabad Unit is bulk drug & intermediate manufacturing unit. It has developed about 50 potential API Key starting materials and also having an outstanding commercial technology. Few key starting materials holds Patent rights and those
Slide 20: Manufacturing Facility Hyderabad Unit
MANUFACTURING FACILTY HYDERABAD UNIT Factory Site R&D Center Synthetic R&D HPLC AR&D QC wet lab 27 Sudarshan Pharma Industries Limited | Investor Presentation
Slide 21: Key Milestone – Global Certifications
Key Milestone – Global Certifications The Company achieved a significant milestone by securing key global certifications for its manufacturing facility in Hyderabad, Telangana. The Company has been awarded the Good Manufacturing Practice (GMP) certification for the manufacturing of API intermediates
Slide 22: Lead Management
Lead Management Mr. Hemal V. Mehta |Chairman & Managing Director Hemal Mehta, Founder-Promoter and Chairman & Managing Director of Sudarshan Pharma Industries Ltd., brings 26 years of extensive experience in the pharmaceutical and chemical manufacturing industry. He is recognized for his expertise i
Slide 23: Board of Directors
Board of Directors Board Vijay Ojha| of Directors Independent Director Jaya Singhania| Independent Director Registered as an Independent Director with the Mr. Vijay Ojha is a result oriented Biotech databank of IICA. She has authored numerous Professional with General Management knowledge write-ups
Slide 24: Board of Directors
Mr. Sanat Bhat| Independent Director Mr. Sanat Bhat is an accomplished finance professional and entrepreneur with over 13 years of experience spanning Transaction Advisory, Investment Banking, and Corporate Governance. A Chartered Accountant (CA) holding an Additional Diploma in International Taxati
Slide 25: Chief Financial Officer
Chief Financial Officer Mr. Sharad Kathawate | Chief Financial Officer A dynamic and results-driven CFO with over 25 years of leadership experience across manufacturing and infrastructure sectors, including start-ups, he brings strong academic credentials with qualifications in M.Com, LLB, AICAI, MB
Slide 26: Senior Consultants
Senior Consultants • Dr. Vishwas Joshi • Dr. S Venkat Rao • Dr. Lanka Rao • Mr. Dhrumit Patel • Dr. Rajesh Patil • Dr. Purshotam Madupu Sudarshan Pharma Industries Limited | Investor Presentation
Slide 27: Senior Key Personnel
Senior Key Personnel 1. Mr. Raju Sanghvi Senior Accountant 7. Mrs. Namrata Mehta Vice President (Sales) 2. Mr. Santosh Thakur Import Manger 8. Mr. Bhavesh Kanakia Vice President - Purchase 3. Mr. Shrinivas Patil Sales Manager 9. Mr. Amit Yadav Finance Manager 4. Mrs. Shrishti Mayekar Sales Head 10.
Slide 28: Senior Key Personnel
Senior Key Personnel 13. Mr. Milan Shah Purchase Manager 19. Mr. Vishal Bhosle Production Head (Jejuri) 14. Mr. Nirav Shah CS & Compliance Officer 20. Mr. Kuldeep Devgude QC (Jejuri) 15. Mr. Vasantrai Mehta President (Admin) 21. Mr. Gummalampati Peda Production head (Hyderabad Unit) 16. Mr. Jatin Me
Slide 29: Our Esteemed Clientele
OUR ESTEEMEDCLIENTELE Sudarshan Pharma Industries Limited | Investor Presentation
Slide 30: Slide 30
Slide 31: India – a strong exporter of pharma & specialty chemicals globally
INDIA- a strong exporter of pharma & Specialty Chemicals Globally A significant and rising player in the Global Pharmaceutical industry India’s drugs and pharmaceutical FDI inflows in the Indian drugs and Pharma exports stood at US$ 27.9 billion in sector reached US$236 Mn. between April FY24 2023-J
Slide 32: Addressing the Opportunity
Addressing the Opportunity The central government has earmarked ~Rs { @ 100 billion for the bulk drug industry, including Rs 30 billion for the promotion of bulk drug 3 parks (for the next five years) and Rs 69.4 billion for a production-linked incentive scheme for the promotion of domestic manufact
Slide 33: Key Problem Area
Key Problem Area Dependence on China for Import of key APIs Categories Imports from China (%) Antibiotics 75-80 Hormones, Prostaglandins, Thromboxane & Leukotrienes 50-55 Pro-Vitamins & Vitamins 55-60 Other heterocyclic compounds 80-85 Other organic compounds 70-75 India imports ~70% of Intermediate
Slide 34: Key Value Proposition
Key value Proposition Why Invest in Sudarshan Pharma Industries Limited Sudarshan Pharma Industries Limited delivers trusted pharmaceutical solutions through a strong focus on quality, compliance, and long-term partnerships. With a robust portfolio of Specialty chemicals , Advanced Intermediates , A
Slide 35: Market Pain Point & Opportunity We Address
Market Pain Point & Opportunity We Address The global pharmaceutical supply chain faces a critical challenge due to high dependency on China for Raw material of specialty chemicals, intermediates and excipients. This dependency exposes manufacturers to price volatility, inconsistent supply, geopolit
Slide 36: Our Solution – The Sudarshan Advantage
Our Solution – The Sudarshan Advantage Sudarshan Pharma Industries Limited | Investor Presentation
Slide 37: Focused Market
FOCUSED MARKET New Export Avenues New Clintele USA Canada China UK Poland Netherlands UAE Jordan Lebanon Oman Qatar Major African Markets Congo Nigeria Cameroon Morocco Uganda Australia Singapore Nepal Taiwan Saudi Rwanda Mali Kenya Ghana Somalia Bangladesh Srilanka Pakistan Algeria Mauritius Sudars
Slide 38: Key Developments in Sudarshan
Key Developments in Sudarshan Sudarshan Pharma Industries Limited | Investor Presentation
Slide 39: R&D for New Molecules & New Technology with Amity University
R&D for New Molecules & New Technology in association with Amity University SPIL has entered into a strategic partnership with Dr. William Selvamurthy at Amity University, a distinguished leader in global education who has established a benchmark for excellence by aligning educational practices, the
Slide 40: New Products & Markets
New Products & Markets Some of Our New Products : New Clientele: Chemical Sector: Pharma Sector: Oncology API’s: • 1, 4-Dioxane • Fluconazole, • Gemcitabine • 2 Methyl THF • Levocetrizine Dihydrochloride, • T9 • Acetonitrile • Chlorozoxazone, • Apalutamide • IODINE • Pregabalin, • Olaparib • Pyridin
Slide 41: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (Rs.Crs) September 2026 September 2025 FYE March 2026 (Unaudited) (Unaudited) (Audited) Revenue from Operations 391.39 314.13 703.06 Cost of Material Consumed/Other Direct Costs 15.24 5.73 39.06 Purchases of Stock-in trade 360.86 310.71 652.13 Change
Slide 42: Financial Metrics: Focus on Margin Optimization and Profit Growth
FinancialMetrics: Focus on Margin Optimizationand Profit Growth Revenue from Operations Operating EBITDA & EBITDA Margin (%) PAT & PAT Margin (%) INR in Crs +39.2% +25.4% +102% 703.0 505.0 49.3 23.3 +83.3% +24% +70.2% 11.5 15.1 388.9 31.1 39.9 231.7 314.1 14.4 8.2 18.2 6.6 Mar 25 Sept 25 Mar 26 FY25
Slide 43: Historical Consolidated Profit & Loss Statement
Historical Consolidated Profit & Loss Statement 31.03.2026 31.03.2025 31.03.2024 PARTICULARS (As per INDAS) (As per INDAS) (As per IGAAP) INCOME Revenue from Operations 703.06 505.05 463.54 Other Income 8.71 2.52 2.61 Total Income (I ) 717.77 507.57 466.15 EXPENSES Cost of Materials Consumed 39.06 8
Slide 44: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet 31.03.2026 31.03.2025 31.03.2024 PARTICULARS (As per INDAS) (As per INDAS) (As per IGAAP) I. EQUITY AND LIABILITIES (1) Shareholder's Funds Share Capital 24.07 24.07 24.07 Reserves and Surplus 132.25 103.52 87.64 (2) Non-Current Liabilities - - Long-Term Borrowi
Slide 45: Powering Healthcare.
Powering Healthcare. ing Markets. Connect 2F-11, 2F-12 SUDARSHAN PHARMA INDUSTRIES LIMITED
Slide 46: Slide 46
Slide 47: Slide 47
Slide 48: Thank you
Thank you a
Sudarshan Pharma Industries — Investor Presentation (August 2026) on 6ix